source · application/json
source_d868d140621d49b6
sha256 3881212fb111f8e43e198e282d9aa9db5f8929227bc66fb366ef7a2f7131f1f6
by researka:v2 · 2026-06-17 11:38:59.797218+04:00
{"publication_id": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757", "traces": [{"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "Across 4 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of serious heart failure events and related cardiovascular composite outcomes in patients with type 2 diabetes and/or heart failure. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "`fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "`fact_id=156141` (`A_core`) — empagliflozin significantly decreases the mortality rate from cardiovascular causes [38% relative risk reduction (RRR)] doi=10.1186/s12933-018-0745-5", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "`fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "`fact_id=193807` (`A_core`) — Canagliflozin reduced the risk of the primary composite outcome by 30% compared to placebo doi=10.4093/dmj.2025.0220", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "Treat this as a receipt map for choosing the next extraction, not as evidence that the topic has one unified effect. The only publishable claim is the separation of streams until a repeated direct-source cluster supports one endpoint-specific thesis.", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1002/ejhf.1732", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/"}, {"doi": "10.1002/ejhf.1978", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "url": null}, {"doi": "10.1186/s12933-018-0745-5", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/"}, {"doi": "10.1161/circulationaha.116.021887", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/"}, {"doi": "10.2174/1573399812666160613113556", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/"}], "claim": "_No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._", "claim_id": "claim_10"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "a3bbb329-ee5b-47f5-b797-dd3b6fd29757",
"researka_submission_id": "258f81c8-eda8-4b8e-b7ec-9d6f18edcb53",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/a3bbb329-ee5b-47f5-b797-dd3b6fd29757/sidecars/citation_traces.json"
}